R. Avant

Conservatively Managed Peyronie's Disease—Long-term Survey Results From Patients Undergoing Nonsurgical and Noninjection Therapies

OBJECTIVE To evaluate patient-reported temporal changes in penile curvature, pain, shortening, sexual function, and quality of life in men undergoing conservative treatment for PD. MATERIALS AND METHODS Of 3840 patients who underwent evaluation at our institution between 1990 and 2012, 719 were randomly selected to receive a mail-in questionnaire with topics including penile curvature, pain, shortening, sexual function, and quality of life. Men endorsing prior intralesional or surgical therapy were excluded. RESULTS A total of 125 patients completed the survey and met the inclusion criteria. The median duration between onset of PD symptoms and survey completion was 8.4 years. Overall, 38% felt that their condition had overall improved and 26% felt that their condition had worsened since onset. Penile curvature resolved in 43%, remained stable in 37%, and worsened in 20%. Twelve percent of the men developed a second de novo curvature. Penile pain occurred in 42%, among whom the pain worsened in 18% and completely resolved in 64%. Sixty-five percent reported penile shortening. Subjective erectile function decreased in 60%, and >40% experienced difficulties with penetrative intercourse. Sexual frequency decreased in 68% of the patients and 59% reported decreased relationship satisfaction. Approximately 50% described negative psychological impacts on self-esteem and image. CONCLUSION The current report provides the most comprehensive and longest-term data on patient-reported outcomes in men undergoing nonsurgical and noninjection therapies. Although approximately 40% of the men reported overall and curvature improvement at a median 8.4-year follow-up, penile length loss, worsening sexual function, relationship dissatisfaction, and psychosocial distress occurred in the majority of PD men.

Impact of anabolic androgenic steroids on sexual function

Background To describe the impact of supra-physiologic anabolic-androgenic steroid (AAS) use, including agent, dosage, and duration of therapy, on sexual function. Methods We reviewed data from an online survey of AAS users to evaluate their sexual function on and off AAS. The online survey consisted of questions addressing demographics, anabolic steroid use and patterns, ancillary medications, testosterone (T)-related symptoms while on and off of therapy, as well as sexual function which was assessed using the 5-item, International Index of Erectile Function (IIEF-5). Results A total of 321 men responded to the survey, of which 90 failed to meet inclusion criteria, for a final cohort of 231 AAS users. The majority of men were Caucasian (85%), employed (62%), and younger than 35 years (58%), while an equal mix were single (47%) or married (46%). The mean IIEF-5 was 22.5, with higher scores associated with increased T dosages (>600 mg/week), use of 17-alpha alkylated hormones and anti-estrogens, and absence of concurrent medical conditions. Lower mean IIEF scores were associated with current and pre-AAS low T symptoms, self-reported angry or violent tendencies, self-reported erectile dysfunction (ED), decreased libido, decreased energy, and depression. After controlling for age, low T symptoms and decreased energy remained significantly associated with lower IIEF scores. Among 127 men reporting de novo decreased libido when not taking AAS, several factors were significantly associated including frequency and duration of T and use of adjunctive therapies, while post-cycle therapies were protective. Men who reported any other de novo symptom (decreased energy, libido, muscle mass or depression) after discontinuing T were also more likely to report de novo ED, as well as those using >10 years or for >40 weeks per year. Conclusions The long-term impact of high dose AAS use on sexual function remains poorly defined. Although high T dosages appeared to be protective of erectile function during use, de novo symptoms such as decreased libido and ED occurred more frequently after discontinuing T, particularly among those using more frequently and for longer durations. Given the importance of these findings, long-term studies evaluating the impacts of discontinuing T on sexual dysfunction are indicated.

Medication patterns and fertility rates in a cohort of anabolic steroid users

Background To describe self-reported medication patterns and fertility rates in a population of anabolic steroid (AS) users. Methods We reviewed data from an online survey of AS users and identified a sub-group who had attempted to achieve a pregnancy with their partners while using AS. The online survey consisted of questions addressing demographics, AS use, ancillary medications, and fertility outcomes. Results A total of 97 men (of 231 total respondents) had attempted to achieve a pregnancy while taking AS and comprise the current cohort. The majority of men were 25–44 years old (63.9%), married (75.5%) and Caucasian (88.7%). Ancillary drug use was common with only 5.2% denying drug use other than ASs. The most common reported ancillary drugs were antiestrogens (89.7%) and sexual enhancement medications (SEMs) (68%). The fertility rate was 92.8%, with 82.4% achieving pregnancy within one year. Interestingly, only 13.5% sought fertility evaluation with treatment required in 8.3%. Age at initiation of AS use, maximum dosage utilized, yearly duration of supplementation, and number of years using steroids were not associated with a prolonged duration to pregnancy or decreased rate of pregnancy. Conclusions Despite continued use of ASs, this cohort’s self-reported fertility rates are unexpectedly high. This is presumably related to cycling of therapy and concomitant use of fertility preserving medications.

Patient’s choice of health information and treatment modality for Peyronie’s disease: a long-term assessment

Despite various Peyronie’s disease (PD) treatment options, the literature is sparse regarding patient preference for available therapies. Our data explore resource and treatment choices made by PD men following diagnosis. A survey was mailed to 719 randomly selected PD men evaluated at our institution from 1990–2012. Questions included evaluation of treatments and preferred information resources. Results were summarized as a descriptive report with statistical analyses performed as indicated. A total of 162 men (median age 65) responded with median PD duration of 9.2 years. Information sources included medical websites (38.9%), physician (35.8%), and books (<1%). Overall, patients felt 72.5% (SD = 40) of physicians had a good understanding of PD. About 53.1% of men had tried at least one therapy with 37.2% trying two or more. In comparing therapies, most surgical patients reported improvement at 82.8%. Among a cohort of PD men responding to a mailed survey, medical websites were the most widely used source of information. Almost half of the patients chose not to pursue any form of therapy, while the remaining majority elected for non-operative intervention. These results suggest a need for greater patient and provider education on PD management.